Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumor × Imatinib Mesylate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 114 Gastrointestinal Stromal Tumors 59 Leukemia 58 Leukemia, Myeloid, Chronic-Phase 41 Precursor Cell Lymphoblastic Leukemia-Lymphoma 33 Blast Crisis 17 Brain Neoplasms 13 Philadelphia Chromosome 11 Neoplasm Metastasis 11 Neoplasms 10 Melanoma 10 Lung Neoplasms 10 Leukemia, Myeloid, Acute 10 Glioblastoma 10 Leukemia, Myeloid, Accelerated Phase 9 Sarcoma 8 Prostatic Neoplasms 8 Gliosarcoma 8 Glioma 8 Leukemia, Myeloid 7 Central Nervous System Neoplasms 7 Primary Myelofibrosis 6 Oligodendroglioma 6 Dermatofibrosarcoma 6 Breast Neoplasms 6 Astrocytoma 6 Small Cell Lung Carcinoma 5 Recurrence 5 Myeloproliferative Disorders 5 Leukemia, Myelomonocytic, Chronic 5

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡